Immunology Program

The Justin Perry Lab

Share
Print
Back to Top

Research

Justin Perry
Justin Perry, PhD

The human body is estimated to remove 1 percent of its body mass, likely more than 200 billion cells, every day. To achieve this, we rely on a highly evolutionarily conserved process: apoptotic cell clearance or efferocytosis. The long-term goal of our lab is to understand how phagocytes handle the immense burden of ingestion and digestion of apoptotic corpses — a process essential for normal development and tissue homeostasis, but also cancer development and progression. We hope to use the information gained through basic studies of efferocytosis to design novel therapeutics.

View Lab Overview

Publications

Morioka, S.*, Perry, J. S. A.*, Raymond, M. H., Medina, C., Onengut-Gumuscu, S., Ravichandran, K. S. Efferocytosis induces a novel SLC program to promote glucose uptake and lactate release. Nature. 563, 714-718. *equal contribution.

Perry, J. S. A., Russler-Germain, E. V., Zhou, Y. W., Purtha, W., Cooper, M. L., Choi, J., Salazar, V., Egawa, T., Lee, B.-C., Abumrad, N. A., Kim, B., Anderson, M., DiPersio, J. F. & Hsieh. C.-S. (2018). Transfer of cell-surface antigens by scavenger receptor CD36 promotes thymic tegulatory T cell receptor repertoire development and allo-tolerance. Immunity. 48(5), 923-936.

View All Publications

People

Justin Perry

Justin Perry, PhD

  • Immunologist Justin Perry investigates homeostatic apoptotic cell clearance and how this process is exploited during cancer development and progression.
  • PhD, Washington University in St. Louis
Lab Affilations

Achievements

  • NIH/NCI Pathway to Independence Award K99/R00 (2019)
  • Burroughs Wellcome Fund – PDEP Award (2018)
  • Cancer Research Institute – Mark Foundation Postdoctoral Fellow (2018)
  • HHMI Hanna H. Gray Fellow Finalist (2017)

Open Positions

Career Opportunities

We are looking for highly motivated and enthusiastic scientists of all levels with an interest in studying fundamental questions of apoptotic cell clearance in any setting or disease context.

Apply now

Disclosures

Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.

MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.

Justin Perry discloses the following relationships and financial interests:

No disclosures meeting criteria for time period


The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.

This page and data include information for a specific MSK annual disclosure period (January 1, 2019 through disclosure submission in spring 2020). This data reflects interests that may or may not still exist. This data is updated annually.

Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at ecoi@mskcc.org.


View all disclosures